Skip to main content
. Author manuscript; available in PMC: 2014 Apr 8.
Published in final edited form as: Exp Neurol. 2009 Sep 4;220(1):191–197. doi: 10.1016/j.expneurol.2009.08.028

Fig. 1.

Fig. 1

The effect of lenalidomide treatment from onset of ALS on motor performance and weights in the G93A SOD1 mice. (A) Lenalidomide-treated mice stayed on the rotarod significantly longer as compared to littermate G93A mice fed on control food. (B) Lenalidomide-treated mice had significantly less weight loss as compared to littermate G93A mice fed on control food. The onset of ALS and the start of lenalidomide treatment, indicated by black arrows. Values are mean+SD. ▲ Lenalidomide-treated G93A mice (n=18). ■ Littermate G93A control mice (n=18) were fed on control food (Chaw without lenalidomide preparation made by Dyets, Inc.).